Nanexa ingår avtal med Novo Nordisk om 46 miljoner

Ny app visar hur synskadade upplever världen

En ny app visar hur allt från grå starr till makuladegeneration och ålderssynthet yttrar sig — ur den synskadades synvinkel. Syftet är att ge seende en inblick i hur personer med synnedsättning uppfattar sin vardag.

Medtech-företag blev årets snabbväxare

Medtech-bolaget Infosolutions toppar årets rankning från Deloitte över Sveriges snabbast växande teknikbolag. På fyra år har bolaget ökat sin omsättning med 12 815 (!) procent.

Bubblarna på innovationslistan

Långt mer än 20 viktiga innovationer som hjälper personer till bättre hälsa har svenska upphovspersoner. Här skriver vi om ett urval av dessa som alla har kommit det senaste halvseklet.

“We are Europe’s hotspot in life science”

The Medicon Valley Alliance has worked for competence development in life science in Denmark and Sweden for a quarter of a century. Anette Steenberg, CEO, sees the anniversary as a recognition of MVA’s explosive power.

He is zooming in on topical preparations

According to Zelmic CEO David Sagna, topical products in drug development is a growing market, and to keep pace with the development, the company is awaiting approval for its new GMP facility.

Klaria tar in finansiering inför ansökan i EU: "Står inför ett transformativt år"

Klaria Pharma har beslutat om en nyemission på upp till 74 miljoner kronor. Syftet är att finansiera fortsatt utveckling och kommersialisering av företagets alginatfilm för drug delivery via munslemhinnan.

ESS i krismöte – varnar för att projektet kan misslyckas

Beatrix Vierkorn, ESS-konsitoriets ordförande, har kallat till krismöte i Lund den 30 november. Det rapporterar Sydsvenska Dagbladet. Anledningen är förseningar och bristande kvalitet på den högteknologiska utrustningen.

The pandemic caused a reshuffle among the world’s vaccine giants – here is the new top list

Fuelled by the pandemic, the power balance in the global vaccine market has completely changed in recent years, a survey from Fierce Pharma shows

Alert from the Swedish Medicines Agency: Many complications with gastric balloons

According to the Swedish Medicines Agency, an increasing number of serious complications are being reported in procedures with gastric balloons as a method for weight loss. The authority fears significant shortcomings in the information to patients both before and after the procedure.

Klaria i spanskt samarbete om munfilm från alger

Uppsalabaserade Klaria Pharma har tecknat avtal med det spanska läkemedelsbolaget Pharmamar om utveckling av en alginatfilmsformulering till en av Pharmamars substanser. En gemensam faktor för bolagen är att bägge utvinner sina produkter ur substanser från havet.

Neutronmöte i Lund samlar hundratals toppforskare

För första gången hålls en konferens knuten till den nya forskningsanläggningen ESS i Lund. Det är Institut Laue-langevin, ILL, i Frankrike och European Spallation Source, ESS, som tillsammans samlar neutronforskare från hela världen.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely expensive treatments with biological drugs. So, how well has Swedish healthcare used biosimilars? The answer partly depends on whom you ask.

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move its production abroad. 34-year-old Thomas was facing an imminent risk of losing his job. However, instead, it actually turned out to be the starting point for one of the biggest success stories in Swedish life science.

Life Science-podden: The perfect moment for an IPO

When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?

Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”

For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the life science sectors of both countries. This year’s event attracted nearly 450 visitors.

Genes from Neanderthals can affect the correct drug dosage

A fifth of all Europeans carry gene variants inherited from Neanderthals, which cause certain drugs to break down more slowly. This may have implications for the drug doses they should take.

Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide

Nanexa skriver avtal med globalt läkemedelsbolag

Det Uppsala-baserade bolaget Nanexa har tecknat ett Material Transfer and Feasibility Study Agreement men en global aktör.

Kirurgveckan på Kistamässan är i full gång

Kirurgveckan är fysisk igen efter pandemin. Och mässhallens takhöjd på Kistamässan gör att sorlet av alla besökare är ljudligt. Utställare från 60-talets företag, föreningar och organisationer finns på plats för att visa upp sina produkter och tjänster.

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s

Amorfa material i centrum när Orexo tar fram nya formuleringar

Snabb upplösning, men med bibehållen stabilitet. Orexos nya drug delivery-plattform tar itu med problematiken hos amorfa material. "Vår teknologi har de positiva egenskaperna hos materialet, och kommer samtidigt runt en del av problemen", säger bolagets

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which he also highlights a study that points out that companies with a high degree of interaction with other companies achieve greater success.

Anna Törner: To kill your darlings

Hopes were high when Anna Törner and her colleague started a study on a dietary supplement that seemed unbelievably good. “Enthusiastically, we dreamed of exciting results and perhaps a publication in a high-impact journal,” she writes in a column.